Global Anti-VEGF Intravitreal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Anti-VEGF Intravitreal Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Anti-VEGF Intravitreal Drugs include Qilu Pharma, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Roche, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences, Biogen and Biocon Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Anti-VEGF Intravitreal Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Anti-VEGF Intravitreal Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Anti-VEGF Intravitreal Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-VEGF Intravitreal Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Anti-VEGF Intravitreal Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Anti-VEGF Intravitreal Drugs sales, projected growth trends, production technology, application and end-user industry.
Anti-VEGF Intravitreal Drugs Segment by Company
Qilu Pharma
Chengdu Kanghong Pharmaceutical
Samsung Bioepis
Roche
Regeneron Pharmaceuticals
Novartis
Coherus BioSciences
Biogen
Biocon Biologics
Anti-VEGF Intravitreal Drugs Segment by Type
Aflibercept
Brolucizumab
Faricimab
Conbercept
Ranibizumab
Other
Anti-VEGF Intravitreal Drugs Segment by Application
Age-related Macular Degeneration
Retinal Vein Occlusion
Diabetic Macular Edema
Other
Anti-VEGF Intravitreal Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Intravitreal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Intravitreal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Intravitreal Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-VEGF Intravitreal Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-VEGF Intravitreal Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-VEGF Intravitreal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Anti-VEGF Intravitreal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Anti-VEGF Intravitreal Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Anti-VEGF Intravitreal Drugs include Qilu Pharma, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Roche, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences, Biogen and Biocon Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Anti-VEGF Intravitreal Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Anti-VEGF Intravitreal Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Anti-VEGF Intravitreal Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-VEGF Intravitreal Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Anti-VEGF Intravitreal Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Anti-VEGF Intravitreal Drugs sales, projected growth trends, production technology, application and end-user industry.
Anti-VEGF Intravitreal Drugs Segment by Company
Qilu Pharma
Chengdu Kanghong Pharmaceutical
Samsung Bioepis
Roche
Regeneron Pharmaceuticals
Novartis
Coherus BioSciences
Biogen
Biocon Biologics
Anti-VEGF Intravitreal Drugs Segment by Type
Aflibercept
Brolucizumab
Faricimab
Conbercept
Ranibizumab
Other
Anti-VEGF Intravitreal Drugs Segment by Application
Age-related Macular Degeneration
Retinal Vein Occlusion
Diabetic Macular Edema
Other
Anti-VEGF Intravitreal Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Intravitreal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Intravitreal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Intravitreal Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-VEGF Intravitreal Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-VEGF Intravitreal Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-VEGF Intravitreal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Anti-VEGF Intravitreal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
187 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-VEGF Intravitreal Drugs Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Anti-VEGF Intravitreal Drugs Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Anti-VEGF Intravitreal Drugs Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Anti-VEGF Intravitreal Drugs Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Anti-VEGF Intravitreal Drugs Market Dynamics
- 2.1 Anti-VEGF Intravitreal Drugs Industry Trends
- 2.2 Anti-VEGF Intravitreal Drugs Industry Drivers
- 2.3 Anti-VEGF Intravitreal Drugs Industry Opportunities and Challenges
- 2.4 Anti-VEGF Intravitreal Drugs Industry Restraints
- 3 Anti-VEGF Intravitreal Drugs Market by Manufacturers
- 3.1 Global Anti-VEGF Intravitreal Drugs Revenue by Manufacturers (2020-2025)
- 3.2 Global Anti-VEGF Intravitreal Drugs Sales by Manufacturers (2020-2025)
- 3.3 Global Anti-VEGF Intravitreal Drugs Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Anti-VEGF Intravitreal Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Anti-VEGF Intravitreal Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Anti-VEGF Intravitreal Drugs Manufacturers, Product Type & Application
- 3.7 Global Anti-VEGF Intravitreal Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anti-VEGF Intravitreal Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anti-VEGF Intravitreal Drugs Players Market Share by Revenue in 2024
- 3.8.3 2024 Anti-VEGF Intravitreal Drugs Tier 1, Tier 2, and Tier 3
- 4 Anti-VEGF Intravitreal Drugs Market by Type
- 4.1 Anti-VEGF Intravitreal Drugs Type Introduction
- 4.1.1 Aflibercept
- 4.1.2 Brolucizumab
- 4.1.3 Faricimab
- 4.1.4 Conbercept
- 4.1.5 Ranibizumab
- 4.1.6 Other
- 4.2 Global Anti-VEGF Intravitreal Drugs Sales by Type
- 4.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Anti-VEGF Intravitreal Drugs Sales by Type (2020-2031)
- 4.2.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2020-2031)
- 4.3 Global Anti-VEGF Intravitreal Drugs Revenue by Type
- 4.3.1 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2020-2031)
- 4.3.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2020-2031)
- 5 Anti-VEGF Intravitreal Drugs Market by Application
- 5.1 Anti-VEGF Intravitreal Drugs Application Introduction
- 5.1.1 Age-related Macular Degeneration
- 5.1.2 Retinal Vein Occlusion
- 5.1.3 Diabetic Macular Edema
- 5.1.4 Other
- 5.2 Global Anti-VEGF Intravitreal Drugs Sales by Application
- 5.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Anti-VEGF Intravitreal Drugs Sales by Application (2020-2031)
- 5.2.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2020-2031)
- 5.3 Global Anti-VEGF Intravitreal Drugs Revenue by Application
- 5.3.1 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2020-2031)
- 5.3.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2020-2031)
- 6 Global Anti-VEGF Intravitreal Drugs Sales by Region
- 6.1 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Anti-VEGF Intravitreal Drugs Sales by Region (2020-2031)
- 6.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Region (2020-2025)
- 6.2.2 Global Anti-VEGF Intravitreal Drugs Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Anti-VEGF Intravitreal Drugs Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Anti-VEGF Intravitreal Drugs Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Anti-VEGF Intravitreal Drugs Revenue by Region
- 7.1 Global Anti-VEGF Intravitreal Drugs Revenue by Region
- 7.1.1 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Anti-VEGF Intravitreal Drugs Revenue by Region (2020-2025)
- 7.1.3 Global Anti-VEGF Intravitreal Drugs Revenue by Region (2026-2031)
- 7.1.4 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Anti-VEGF Intravitreal Drugs Revenue (2020-2031)
- 7.2.2 North America Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Anti-VEGF Intravitreal Drugs Revenue (2020-2031)
- 7.3.2 Europe Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Anti-VEGF Intravitreal Drugs Revenue (2020-2031)
- 7.4.2 Asia-Pacific Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Qilu Pharma
- 8.1.1 Qilu Pharma Comapny Information
- 8.1.2 Qilu Pharma Business Overview
- 8.1.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolio
- 8.1.5 Qilu Pharma Recent Developments
- 8.2 Chengdu Kanghong Pharmaceutical
- 8.2.1 Chengdu Kanghong Pharmaceutical Comapny Information
- 8.2.2 Chengdu Kanghong Pharmaceutical Business Overview
- 8.2.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolio
- 8.2.5 Chengdu Kanghong Pharmaceutical Recent Developments
- 8.3 Samsung Bioepis
- 8.3.1 Samsung Bioepis Comapny Information
- 8.3.2 Samsung Bioepis Business Overview
- 8.3.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolio
- 8.3.5 Samsung Bioepis Recent Developments
- 8.4 Roche
- 8.4.1 Roche Comapny Information
- 8.4.2 Roche Business Overview
- 8.4.3 Roche Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Roche Anti-VEGF Intravitreal Drugs Product Portfolio
- 8.4.5 Roche Recent Developments
- 8.5 Regeneron Pharmaceuticals
- 8.5.1 Regeneron Pharmaceuticals Comapny Information
- 8.5.2 Regeneron Pharmaceuticals Business Overview
- 8.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolio
- 8.5.5 Regeneron Pharmaceuticals Recent Developments
- 8.6 Novartis
- 8.6.1 Novartis Comapny Information
- 8.6.2 Novartis Business Overview
- 8.6.3 Novartis Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Novartis Anti-VEGF Intravitreal Drugs Product Portfolio
- 8.6.5 Novartis Recent Developments
- 8.7 Coherus BioSciences
- 8.7.1 Coherus BioSciences Comapny Information
- 8.7.2 Coherus BioSciences Business Overview
- 8.7.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolio
- 8.7.5 Coherus BioSciences Recent Developments
- 8.8 Biogen
- 8.8.1 Biogen Comapny Information
- 8.8.2 Biogen Business Overview
- 8.8.3 Biogen Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Biogen Anti-VEGF Intravitreal Drugs Product Portfolio
- 8.8.5 Biogen Recent Developments
- 8.9 Biocon Biologics
- 8.9.1 Biocon Biologics Comapny Information
- 8.9.2 Biocon Biologics Business Overview
- 8.9.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolio
- 8.9.5 Biocon Biologics Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Anti-VEGF Intravitreal Drugs Value Chain Analysis
- 9.1.1 Anti-VEGF Intravitreal Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Anti-VEGF Intravitreal Drugs Production Mode & Process
- 9.2 Anti-VEGF Intravitreal Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Anti-VEGF Intravitreal Drugs Distributors
- 9.2.3 Anti-VEGF Intravitreal Drugs Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
